- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Patient Resources
About This Event
Genetic Testing In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Live Q&A With Dr Neera DahlPolycystic Kidney Disease (PKD) is the most commonly inherited disease that can lead to kidney failure.1 Genetic testing is becoming more affordable and its use in the detection of autosomal dominant polycystic kidney disease (ADPKD) mutations for diagnostic and research purposes is more widespread.1 Please join us as our leading expert, Neera Dahl, MD, PhD unravels the complexities of genetic testing in ADPKD, recommendations on when genetic testing is appropriate and indicated, and the different types of molecular genetic tests available. She will also discuss the information provided in a typical clinical genetic report and interpretation of the same. References:
- Ali H, et al. (2019). Sci Rep. 9:4141.
Yale School of Medicine*
Neera Dahl, MD, PhD is currently a clinician-educator and a Professor of Medicine at Yale University, School of Medicine, Section of Nephrology. She received her MD and PhD from Tufts University School of Medicine and completed her residency and fellowship at the Beth Israel Deaconess Medical Center, in Boston, MA. She has been instrumental in developing the Yale Inherited Kidney Disease Clinical Program and is the principal investigator for several ongoing clinical trials in ADPKD. She maintains an active ADPKD registry and is involved in research exploring the role of inflammation and fibrosis in the progression of ADPKD. She is also the director of the Yale Nephrology Clinical Trials Program and a member of the Scientific Advisory Board for the Polycystic Kidney Disease Foundation.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Sachin Hajarnis, PhD is a Senior Clinical and Scientific Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.
*Dr Dahl is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Hajarnis is an employee of OPDC.
If you would like to register for the 6:00 pm to 7:00 pm EDT broadcast, please click below:
Audio/Podcast December 14, 2022
In this podcast, Dr Edgar Lerma will present an overview of IgA nephropathy and a stepwise approach to identify and diagnose patients.
Downloadable Resource July 15, 2022
This downloadable resource provides an overview of the PKD Foundation’s Centers of Excellence Program.
Downloadable Resource August 11, 2020
This presentation will discuss the pathophysiology, disease progression, and the physical & emotional burden of autosomal dominant polycystic kidney disease (ADPKD). The key factors that play into ADPKD disease diagnosis…
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
January 31 from 12:00 pm to 1:00 pm
February 14 from 12:00 pm to 1:00 pm
- Resource Center
- Patient Resources